Oculis (NASDAQ:OCS) Shares Down 4.6% - Should You Sell?

Key Points

• Oculis shares fell 4.6% to about $10.95 in light trading, with volume down 98% from its average session volume.
• Despite several analysts cutting price targets, coverage remains largely positive: nine analysts rate the stock Buy versus one Sell, with a Moderate Buy consensus and an average target of $38.
• The clinical-stage biotech reported a quarterly loss of $0.20 per share on just $0.38 million in revenue, while analysts expect a full-year loss of $2.01 per share; institutional investors own 22.3% of the company.

Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s share price fell 4.6% during mid-day trading on Friday . The stock traded as low as $11.15 and last traded at $10.9450. 10,477 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 444,602 shares. The stock had previously closed at $11.47.

Analyst Ratings Changes

A number of equities analysts have issued reports on OCS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a research note on Friday, July 17th. JPMorgan Chase & Co. lowered their price target on Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Robert W. Baird decreased their price objective on shares of Oculis from $49.00 to $38.00 and set an "outperform" rating for the company in a report on Monday, June 1st. Stifel Nicolaus decreased their price objective on Oculis from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, June 1st. Finally, Guggenheim dropped their target price on shares of Oculis from $75.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, June 1st. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $38.00.

Oculis Stock Performance

The company has a market capitalization of $632.97 million, a price-to-earnings ratio of -6.28 and a beta of 0.52. The stock's 50 day moving average price is $12.45 and its 200 day moving average price is $19.68. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The firm had revenue of $0.38 million for the quarter. Analysts expect that Oculis Holding AG will post -2.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OCS. Braidwell LP bought a new stake in Oculis in the 2nd quarter valued at about $11,570,000. NEXTBio Capital Management LP acquired a new position in Oculis in the 4th quarter valued at $2,991,000. Folketrygdfondet acquired a new stake in shares of Oculis during the 4th quarter worth $3,651,000. Simplify Asset Management Inc. bought a new position in shares of Oculis in the fourth quarter worth $1,972,000. Finally, Propel Bio Management LLC acquired a new stake in shares of Oculis in the 4th quarter valued at $3,452,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.